Screener
Allogene Therapeutics ALLO Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | Amortized Cost | Unrealized Gains | Unrealized Losses | Fair Value |
|---|---|---|---|---|
| Corporate bonds | 69,145 | 10 | (55) | 69,100 |
| U.S. treasury securities | 61,791 | 52 | (9) | 61,834 |
| U.S. agency securities | 18,909 | 2 | (7) | 18,904 |
| Total cash equivalents and investments | $261,815 | $66 | $(249) | $261,632 |
| Classified as: | ||||
| Cash equivalents | $25,055 | |||
| Short-term investments | 236,577 | |||
| Long-term investments | — |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's unrealized losses on investments (before tax)?
- Allogene Therapeutics (ALLO) reported unrealized losses on investments (before tax) of $249K in Q1 2026.
- How has Allogene Therapeutics's unrealized losses on investments (before tax) changed year-over-year?
- Allogene Therapeutics's unrealized losses on investments (before tax) increased by 154.1% year-over-year, from $98K to $249K.
- What is the long-term trend for Allogene Therapeutics's unrealized losses on investments (before tax)?
- Over 5 years (2020 to 2025), Allogene Therapeutics's unrealized losses on investments (before tax) has grown at a -28.4% compound annual growth rate (CAGR), from $53K to $10K.
Ask your AI about Allogene Therapeutics's unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude